Full-Time

Warehouse General Manager

Posted on 9/17/2025

Deadline 10/8/25
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Birmingham, UK

In Person

Some UK travel required, with overnight stays and attendance at meetings or conventions outside of normal business hours, including some evenings and weekends.

Category
Operations & Logistics (2)
,
Required Skills
Inventory Management
Data Analysis
Requirements
  • Proven experience in warehouse operations management, with significant leadership experience (managing managers as direct reports) in an automated warehouse environment within a set budget is essential
  • Proven track record in designing and delivering projects to stabilise and develop warehouse operations
  • Excellent leadership, communication and problem-solving skills to lead and develop teams in large, complex 24/7 operation
  • Experience of leading teams in a fast moving and changing environment
  • Ability to work in a warehouse environment; Including standing and walking for extended periods. Ability to lift and move materials as needed. Comfortable working in varying temperatures within the warehouse environment
  • Experience of warehouse management systems (WMS) and automated technologies. Strong knowledge of Microsoft Office 365 and warehouse software with the ability to navigate between multiple systems seamlessly
  • Experience in the pharmaceutical industry is highly preferred
  • Knowledge and experience of regulatory compliance and quality standards in pharmaceutical distribution is highly preferred
  • Proficiency in data analysis and performance metrics including KPIs, strong problem-solving skills and high attention to detail
  • Ability to build strong and effective relationships across departments, demonstrating a collaborative approach
  • Excellent organisational abilities
Responsibilities
  • Implement operational strategies to improve productivity and efficiency in line with company requirements
  • Prioritises tactical actions to improve service and cost performance within the operations team and make recommendations for improvements
  • Working with people leaders to develop a culture of continuous improvement across the central logistics centre and making recommendations to the Head of CLC
  • Promote and enforce a safe working environment, ensuring compliance with health and safety regulations
  • Deputise for the Head of CLC in their absence
  • Lead, mentor, and develop a multi-skilled operations team
  • Support with coaching, direction, development and guidance in line with our Guiding Principles including hiring, training, performance evaluations
  • Foster a positive and collaborative work environment, encouraging teamwork and continuous improvement
  • Embracing a learning and development culture across within the function liaising with L&D team to maximise output
  • Support teams to achieve participation levels in employment engagement surveys to drive action plans
  • Conduct performance reviews and provide timely feedback to all team members according to the company’s annual appraisal process
  • Champion and lead DE&I, embracing an open dialogue and collaboration as part of the sites culture, empowering sharing of different perspectives, ensuring a culture of feeling valued, respected, and supported
  • Recruit, train and develop all direct reports
  • Be a role model by demonstrating the Guiding Principles in the everyday and continuously work towards the Cencora Purpose
  • Provide effective leadership and motivation through regular team briefings
  • Monitor key performance indicators (KPI’s) and operational metrics to drive performance against service, compliance, productivity and cost in line with targets and ensure the implementation of actions to reverse identified areas of under-performance
  • Identify opportunities for process improvement and implement best practice
  • Responsible for correct headcount to maintain both service and productivity measures in operations according to all relevant KPI’s
  • Support efficiency and optimisation of automated systems and equipment to ensure effective operations
  • Collaborate with IT, Knapp and technical teams to troubleshoot and resolve any automation-related issues
  • Working with the Quality Support Manager ensuring CLC is operating in accordance with standards expected from regulatory bodies such as GDP, MHRA, Home Office, ICO. Monitor and manage compliance in line with these standards
  • Ensure the department meets all Health & Safety requirements and Direct Reports are aware of their responsibilities and compliant to the Standard Operating Procedures (SOP’s)
  • Conduct regular audits and inspections to maintain compliance and address any deficiencies
  • Maintain high standards of quality and accuracy in all warehouse operations, ensuring that pharmaceutical products are handled and stored correctly
  • Support the Quality team to ensure all procedures are followed within Operations to secure the integrity of products
  • Effectively implement inventory management procedures related to Inbound and Outbound processes in line with company guidelines, working in partnership with the Risk and compliance manager and Inventory & Returns manager to manage inventory levels
  • Identify and implement continuous improvement initiatives to enhance operational efficiency and productivity
  • Develop and manage the warehouse and overhead budgets
  • Monitor expenses and ensure cost-effective operations
  • Identify and implement cost-saving initiatives
  • Build and maintain relationships with internal and external stakeholders
  • Collaborate with other departments, aligning warehouse operations with organisational goals to ensure seamless operations and customer satisfaction
  • Participate in cross-functional meetings to align warehouse activities with business objectives
  • Address and resolve any operational issues or challenges
  • Provide prompt feedback to queries raised by other departmental managers and act swiftly to warehouse service issues raised by customers
  • Champion and lead the Health and Safety culture as well as continuous improvement through best practice activities in accordance to the SOP’s
  • Working with the H&S Manager conduct regular safety audits and risk assessments
  • Commit to advancing our ESG initiatives to create healthier futures around the world
  • Ensure a culture of being safe, legal and compliant.
Desired Qualifications
  • Experience in the pharmaceutical industry is highly preferred
  • Knowledge and experience of regulatory compliance and quality standards in pharmaceutical distribution is highly preferred

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE